Picture of Denali Therapeutics logo

DNLI — Denali Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Denali Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* Denali Therapeutics Inc  DNLI.OQ  reported a quarterly
adjusted
loss of 68 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -80 cents.  The mean expectation of
sixteen analysts for the quarter was for a loss of 70 cents per
share. Wall Street expected results to range from -86 cents
to -53 cents per share.
    * Reported revenue was zero​; analysts expected $14.02
million. 
    * Denali Therapeutics Inc's reported EPS for the quarter was
a
loss of 68 cents​.
    * The company reported a quarterly loss of $101.8 million.
    * Denali Therapeutics Inc shares had fallen by 16.5% this
quarter and lost 20.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 14.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Denali
Therapeutics Inc is $35.50 
This summary was machine generated from LSEG data May 7 at 09:12
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.70          -0.68          Beat
 Dec. 31 2023      -0.80          -0.86          Missed
 Sep. 30 2023      -0.80          -0.72          Beat
 Jun. 30 2023      -0.68          1.30           Beat

Recent news on Denali Therapeutics

See all news